U.S. National Phase of PCT/EP2003/008926

Serial No.: Unassigned

February 4, 2005

IN THE CLAIMS:

Amend the claims as follows:

1. (Original) A product comprising:

a first component which is a scaffold;

a second component which is an adjuvant; and

a third component which is an antigen.

2. (Original) A product according to claim 1 wherein the second component is a

polypeptide which is a ligand for CD21 or a cell surface molecule on B cells or T cells or

follicular dendritic or other antigen presenting cells

3. (Currently Amended) A product according to claim 1 or 2 wherein the third

component is a polypeptide antigen.

4. (Currently Amended) A product according to claim 1 or 2 wherein the third

component is a non-polypeptide antigen.

5. (Currently Amended) A product according to any one of claims 1 to 3 claim 1

wherein the scaffold and antigen are the same.

6. (Original) A product according to claim 5 wherein the scaffold and antigen are

- 3 -

923406

U.S. National Phase of PCT/EP2003/008926

Serial No.: Unassigned

February 4, 2005

a viral coat protein.

7. (Original) A product according to claim 6 wherein the viral coat protein is

Hepatitis B surface antigen.

8. (Currently Amended) A product according to any one of claims 1 to 3 claim 1

wherein the scaffold and adjuvant are the same.

9. (Original) A product according to claim 8 wherein the scaffold and adjuvant

are C4bp core protein.

10. (Currently Amended) A pharmaceutical composition comprising the product

of any one of claims 1 to 9 claim 1 together with a pharmaceutically acceptable carrier

or diluent.

11. (Currently Amended) A method of inducing an immune response to an

antigen which method comprises administering to a subject an effective amount of a

product according to any one of claims 1 to 10 claim 1.

12. (Original) A method of making a product comprising:

a first component which is a polypeptide scaffold;

a second component which is a polypeptide which is a ligand for CD21 or

- 4 -

923406

U.S. National Phase of PCT/EP2003/008926

Serial No.: Unassigned

February 4, 2005

a cell surface molecule on B cells or T cells or follicular dendritic or other antigen presenting cells; and

a third component which is a polypeptide antigen,

the method comprising expressing nucleic acid encoding the three components in the form of a fusion protein, and recovering the product.

13. (Original) A method of making a product comprising:

a first component which is a polypeptide scaffold;

a second component which is a polypeptide which is a ligand for CD21 or a cell surface molecule on B cells or T cells or follicular dendritic or other antigen presenting cells; and

a third component which is a non-polypeptide antigen,

the method comprising expressing nucleic acid encoding the first and second components in the form of a fusion protein, joining said fusion protein to the third component, and recovering the product.

- 14. (Currently Amended) The method of claim 12 or 13 wherein the nucleic acid is expressed in a prokaryotic host cell.
- 15. (Original) A method according to claim 14 wherein the fusion protein is recovered in multimeric form.

U.S. National Phase of PCT/EP2003/008926

Serial No.: Unassigned

February 4, 2005

16. (Original) A method according to claim 15 wherein the recombinant protein is

present at least at a concentration of at least 2 mg/l of cell culture.

17. (Currently Amended) A method according to claim 15 or claim 16 wherein

the host prokaryotic cell is *E. coli*.

18. (Original) An expression vector comprising a nucleic acid sequence

encoding a fusion protein of

a first component which is a polypeptide scaffold;

a second component which is a polypeptide which is a ligand for CD21 or

a cell surface molecule on B cells or T cells or follicular dendritic or other antigen

presenting cells; and optionally

a third component which is a polypeptide antigen,

operably linked to a promoter functional in a host cell.

19. (Original) A bacterial host cell transformed with the expression vector of

claim 18.

20. (Original) A eukaryotic host cell transformed with the vector of claim 18.

21. (Original) Use of the expression vector of claim 20 in a method of treatment

of the human or animal body.